Johnson & Johnson has announced that it will be contributing vaccines to support the Rwandan immunisation programme to combat Ebola.
List view / Grid view
Research & Development (R&D)
Filter the results
The US Food and Drug Administration has awarded APR-TD011 Orphan Drug Designation, for the treatment of a rare disease.
The FDA and EMA have granted Orphan Drug Designation to zotiraciclib, currently the subject of two separate Phase Ib clinical trials in glioblastoma.
Dr Sodergren explores the uses of medical cannabis, describing its applications. He also discusses the future of cannabinoid research in the short- and long-term.
To further its investigation into the cause of the NDMA impurities found in ranitidine and nizatidine, the FDA has asked manufacturers of these products to expand their testing to include all lots of the medication.
A new slow-release formulation and delivery system for the oral contraceptive pill has shown success in pre-clinical trials and could be taken once a month.
Astellas has announced that it will be acquiring Audentes Therapeutics at a total cost of $3 billion.
The UK NICE has extended its approval for olaparib, updating its formulation from eight capsules twice a day to two tablets twice daily.
Scientists have proposed combining ultrasound with other techniques to improve drug transport into brain tumours.
The US Food and Drug Administration has announced new guidance for drug applications that include results from adaptive clinical trials.
The ABPI’s board has unanimously appointed Dr Richard Torbett as Chief Executive, commencing 1 January 2020.
The US FDA has awarded pemigatinib Priority Review, after the drug met its primary and secondary endpoints in a Phase II trial.
NICE has approved palbociclib through the Cancer Drugs Fund, meaning that women with advanced breast cancer who have already received hormone therapy will now be eligible for palbociclib on the NHS.
The three largest UK political parties have published their manifestos for the upcoming election which focus on various pharma initiatives including the NHS, R&D, drug prices and mental health.